Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0
|
作者：
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp Salamanca, Salamanca, Spain
[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA
[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[11] Med Coll Wisconsin, Milwaukee, WI USA
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[16] Janssen Res & Dev, Spring House, PA USA
[17] Janssen Res & Dev, Antwerp, Belgium
[18] Janssen Biol Europe, Leiden, Netherlands
[19] Freiburg Univ, Med Ctr, Freiburg, Germany
[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[21] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8003
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
    Mateos, Maria-Victoria
    Richardson, Paul
    Weisel, Katja
    Moreau, Philippe
    San-Miguel, Jesus
    Goldschmidt, Hartmut
    Orlowski, Robert
    Sonneveld, Pieter
    Reece, Donna E.
    Suzuki, Kenshi
    Bahlis, Nizar
    Yoon, Sung-Soo
    Spencer, Andrew
    Nooka, Ajay
    Hungria, Vania
    Plesner, Torben
    Ben Yehuda, Dina
    Pei, Huiling
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S179 - S180
  • [42] Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma (RRMM) - final efficacy and safety results
    Ocio, Enrique
    Efebera, Yvonne
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria-Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul
    Norin, Stefan
    Obermuller, Jakob
    Bakker, Nicolaas
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S204 - S204
  • [43] DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
    Lokhorst, H.
    Laubach, J.
    Nahi, H.
    Plesner, T.
    Gimsing, P.
    Hansson, M.
    Minnema, M.
    Lassen, U.
    Krejcik, J.
    Ahmadi, T.
    Khan, I.
    Uhlar, C.
    Lisby, S.
    Basse, L.
    Brun, N.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 106 - 107
  • [44] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
    Orlowski, Robert
    Delimpasi, Sosana
    Straub, Jan
    Symeonidis, Argiris
    Pour, Ludek
    Hajek, Roman
    Touzeau, Cyrille
    Bhanderi, Viralkumar
    Pavlicek, Petr
    Robak, Pawel
    Berdeja, Jesus G.
    Matous, Jeffrey V.
    Karlin, Lionel
    Zweegman, Sonja
    Grosicki, Sebastian
    Pluta, Andrzej
    Kambhampati, Suman
    Suryanarayan, Kaveri
    Twumasi-Ankrah, Philip
    Dash, Ajeeta
    Labotka, Richard
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
  • [45] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
    Siegel, David Samuel DiCapua
    Schiller, Gary J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin W.
    Seet, Christopher
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand Marquess
    Fonseca, Gustavo
    Reece, Donna Ellen
    Zafar, Faiza
    Chung, Weiyuan
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Quach, Hang
    Dimopoulos, Meletios A.
    Rodriguez-Otero, Paula
    Berdeja, Jesus G.
    Richardson, Paul G.
    Kyada, Margee
    Chu, Shuyu
    Chen, Min
    Abad, Patricia C.
    Morando, Juliane
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [48] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    Yeh, Howard
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [49] Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018
    Merz, Maximilian
    Patel, Vishal
    Kutikova, Lucie
    Lebioda, Andrea
    Schoehl, Martina
    Kellermann, Lenka
    Goldschmidt, Hartmut
    BLOOD, 2019, 134
  • [50] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
12345